科研之友
微信
新浪微博
Facebook
分享链接
摘要
Purpose: To assess the efficacy of combined therapy of chemotherapy and cytokine-induced killer (CIK) cells on treatment of multiple types of soft tissue tumors with overall survival (OS). Methods: Pooling all data together, we assessed the effect of combination of chemotherapy and CIK cells therapy on 1-year, 2-year, 3-year and 5-year OS. Similar subgroup was also performed on colorectal and gastric tumors. The overall odds ratio (OR) and its corresponding 95% confidence interval (95% CI) for each analysis were calculated, respectively. Results: For soft tissue cancer, the chemotherapy plus CIK cells therapy significantly improved the 2-year, 3-year and 5-year OS (2-year: OR=1.19, 95% CI: 1.01-1.41, p=0.039; 3-year: OR= 1.35, 95% CI: 1.19-1.54, p=0.000; 5-year: OR= 1.86, 1.32-2.63, p=0.000), indicating better survivals occurred with the adjuvant CIK cells therapy 2 years, 3 years and 5 years after treatment compared to the conventional chemotherapy alone. We performed the subgroup analysis in colorectal and gastric tumors, the combination of chemotherapy and CIK cells therapy significantly improved the 5-year OS (OR=1.77, 95% CI: 1.25-2.51, p=0.001) for gastric cancer patients with the chemotherapy plus CIK cells treatment, whereas for colorectal cancer, it could not be improved after the combination therapy. Conclusion: The combination of chemotherapy and CIK cells treatment improves the OS for patients with soft tissue cancer, especially for gastric cancer patients. The combined therapy of chemotherapy and CIK cells treatment should be recommended for patients with multiple types of soft tissue tumors.
- 出版日期2017
- 单位川北医学院
